Corporate Finance

Amid market volatility, industrial leaders are ditching traditional models for an integrated approach that promises speed, cost certainty, and less risk.

A seismic shift is underway as affluent buyers trade Toronto and Vancouver for emerging hubs, driven by economic diversification and a new definition of value.

Axi secures a key license in Mauritius, unlocking a strategic path into Africa and Asia. But is it a simple expansion or a savvy play in regulatory arbitrage?

As drills break ground at the massive Tanbreez project, can one company's Arctic gamble secure a new rare earth supply chain for the Western world?

Toronto-based Augmenta has launched ACP 2.0, an AI platform that claims to slash electrical design work from weeks to hours, offering a strategic solution to labor shortages.

Gelteq aims to replace needles with its ingestible gel, targeting diabetes and more. But can it balance this lofty goal with near-term revenue and tight finances?

A new Cypriot-operated fintech launches with Finnish IBANs. We analyze if this bet on 'Nordic reliability' is a viable strategy in the EU's crowded market.

Mount Sinai School District partners with Ameresco on a budget-neutral energy overhaul, showcasing a model for taxpayer savings and hands-on STEM education.

Beyond the accolades, Delinea's top ranking in growth and innovation reveals a market pivoting to manage the silent rise of machine and AI identities.

A BofA study reveals a seismic shift in wealth, where longer lives and a generational split over crypto are creating unprecedented financial complexity.

A new partnership opens institutional private credit to thousands of advisors. But what are the real opportunities and hidden risks behind this "democratization"?

As enterprises deploy autonomous AI agents, a new class of threats emerges. A startup founded by Cisco veterans says it can stop attacks before they happen.

A new report reveals AI isn't the problem in finance; it's the data. Weak foundations are costing firms billions and exposing a critical industry blind spot.

Insilico Medicine's AI-designed drug, ISM8969, enters human trials, targeting chronic neuroinflammation by crossing the elusive blood-brain barrier.

A new report from resale giant StockX maps the hottest products, but a closer look reveals a complex economy of hype, hero-worship, and national pride.

A new mid-year outlook reveals how geopolitical turmoil, the AI boom, and a renewed focus on sovereignty are reshaping investment strategies for a volatile H2 2026.

Glass House Brands follows a new playbook, splitting its business to chase a NYSE listing. Is this the key that unlocks institutional capital for the entire sector?

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

Armlogi Holding Corp. is betting big on operational upgrades for the summer e-commerce rush. But can these costly moves pay off for the small-cap logistics firm?